Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA® Shows Positive Outcome in Treatment of Antiretroviral-Naïve HIV Patients
Janssen’s new once-daily, single tablet combination therapy SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]) has shown to be both highly effective and well-tolerated in treating antiretroviral-naïve HIV-1 patients through 48 weeks in the pivotal phase 3 AMBER study.1 The results of this study will be presented on 27 October 2017 at the 16th European AIDS Conference (EACS) in Milan, Italy.
Findings from the study demonstrated that the single tablet regimen (STR) D/C/F/TAF provided effective and durable viral suppression, meaning most patients achieved an undetectable viral load, whilst offering the high genetic barrier to resistance of darunavir, for ART-naïve HIV-1-infected patients.1
“The AMBER study results show that the boosted darunavir-based STR which also contains F/TAF was a highly effective regimen with favourable kidney and bone safety laboratory parameters compared to F/TDF (emtricitabine/tenofovir disoproxil fumarate). It was very well-tolerated, and doses in a single daily tablet,” said Chloe Orkin, Chair of the British HIV Association (BHIVA) and Consultant Physician at the Royal London Hospital.
AMBER is a Phase 3 randomised double-blind non-inferiority international study designed to assess the efficacy and safety of D/C/F/TAF versus the control in HIV-1 positive treatment-naïve adult patients over 48 weeks. The control comprised two separate medications – a tablet of darunavir/ cobicistat (D/C) plus a tablet of emtricitabine/ tenofovir disoproxil fumarate (F/TDF). The primary endpoint was non-inferiority of the STR versus the control regarding the proportion of patients with a viral load (VL) of less than 50 copies per mL at 48 weeks (per FDA snapshot analysis).1 Reducing their viral load to an undetectable level is a key treatment goal for HIV patients, enabling their immune system to strengthen and leading to improved quality of life.2
The single tablet D/C/F/TAF demonstrated durable non-inferiority versus the control group over 48 weeks (HIV RNA <50 c/ml 91.4% vs 88.4% respectively, difference 2.7%; 95% CI: −1.6 to 7.1) and also produced low virologic failure rates (VL≥50 c/mL; FDA-Snapshot: 4.4% (16/362) versus 3.3% (12/363)).1 The high efficacy results were consistent across different subgroups of patients. No treatment-emergent mutations related to darunavir, primary protease inhibitors or tenofovir (TFV) were observed. The STR showed improved bone and renal safety laboratory parameters, along with similar safety versus control through 48 weeks, in terms of rates of discontinuations due to adverse events (AEs – 1.9% vs. 4.4%), of Grade 3-4 AEs (5.2% vs 6.1%), and of serious AEs (4.7% vs. 5.8%).1 D/C/F/TAF also demonstrated a similar total cholesterol/HDL cholesterol ratio, with limited lipid changes.1
D/C/F/TAF safety and efficacy were also demonstrated in the open label Phase 3 48-week EMERALD study, a switch trial amongst virologically suppressed ART experienced patients.3
“Janssen’s mission in HIV is the delivery of transformational innovations to meet the diverse needs of the HIV community and to offer simple yet effective solutions to reduce the burden on those affected by this disease. The recent European approval of D/C/F/TAF coupled with the AMBER results mean that we can offer the community a new treatment option, highly effective at achieving viral suppression, for HIV-1 patients about to embark on their first antiretroviral therapy,” said Brian Woodfall, MD, Global Head of Late Development, Infectious Diseases and Vaccines, Janssen.
D/C/F/TAF is the first once-daily darunavir-based single-tablet regimen (STR), and recently received European Commission approval on 21 September 2017.4 In the U.S., D/C/F/TAF is an investigational product and has not been proven to be safe or efficacious. A new drug application (NDA) was filed on 22 September 2017 with the U.S. Food and Drug Administration (FDA) and is currently awaiting approval.5
D/C/F/TAF has been developed by Janssen to provide HIV patients with a convenient once-daily, single tablet that provides highly effective viral suppression through the combined action of darunavir, cobicistat, emtricitabine and tenofovir alafenamide. Furthermore, the new STR comes with the high genetic barrier to viral resistance development provided by darunavir and the favourable renal and bone safety profile seen with tenofovir alafenamide.3
Notes to editors
On 23 December 2014, Janssen and Gilead Sciences International Ltd amended a licensing agreement for the development and commercialisation of a once-daily STR combination of darunavir and Gilead's TAF, emtricitabine and cobicistat. Under the terms of the agreement, Janssen and its affiliates are responsible for the manufacturing, registration, distribution and commercialisation of this STR worldwide.
About SYMTUZA ®
In the European Union, SYMTUZA® is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with a body weight at least 40 kg). Genotypic testing should guide the use of SYMTUZA®.6
SYMTUZA® is a fixed-dose combination of four active substances (darunavir, cobicistat, emtricitabine and tenofovir alafenamide), available as 800 mg/150 mg/200 mg/10 mg film-coated tablets. Darunavir inhibits the HIV protease and prevents the formation of mature infectious virus particles. Emtricitabine and tenofovir alafenamide are substrates and competitive inhibitors of HIV reverse transcriptase. After phosphorylation, they are incorporated into the viral DNA chain, resulting in chain termination. Cobicistat enhances the systemic exposure of darunavir and has no direct antiviral effect.6
About the AMBER trial
AMBER is a Phase 3, randomised, active-controlled, double-blind, international, multicentre, parallel-group, non-inferiority study. Subjects were randomly assigned (362 D/C/F/TAF and 363 control) and treated. The primary endpoint was non-inferiority of D/C/F/TAF versus control regarding the proportion of patients with viral load [VL] <50 copies per mL (FDA-snapshot analysis) at 48 weeks (10% margin).1
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/emea/ and follow us at @JanssenEMEA.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of potential preventive and treatment regimens for HIV. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new indications and therapeutic combinations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the year ended January 1, 2017, including under “Item 1A Risk Factors,” its most recently filed Quarterly Report on Form 10-Q, including in the section captioned “Cautionary Note Regarding Forward-Looking Statements,” and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
Content disclaimer: EACS is not responsible for the content
1. Gallant J, Orkin C, Molina JM, et al. Week 48 results of AMBER: A Phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naïve HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/ tenofovir disoproxil fumarate (FTC/TDF). Abstract PS8/2 to be presented at 16th European AIDS Conference, Milan, Italy, 25-27 October 2017.
2. NHS Choices. HIV and AIDS. Available at: http://www.nhs.uk/conditions/hiv/Pages/Introduction.aspx Last accessed October 2017
3. Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a Phase 3, randomised, non-inferiority trial. Lancet HIV. 2017 Oct 5 [epub ahead of print].
4. European Medicines Agency. Symtuza® product details. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004391/human_med_002165.jsp&mid=WC0b01ac058001d124 Last accessed October 2017.
5. Johnson & Johnson. Janssen announces pivotal Phase 3 study results for investigational darunavir-based single-tablet regimen for the treatment of HIV-1 infection in adults switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens. Press release October 6, 2017. Available at: https://www.jnj.com/media-center/press-releases/janssen-announces-pivotal-phase-3-study-results-for-investigational-darunavir-based-single-tablet-regimen-for-the-treatment-of-hiv-1-infection-in-adults-switching-from-boosted-protease-inhibitors-plus-emtricitabine-and-tenofovir-disoproxil-fumarate-regimens Last accessed October 2017.
6. Symtuza® summary of product characteristics, October 2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004391/WC500235524.pdf Last accessed October 2017.
+ 33 6 88 09 33 35
Phone: +1 732-524-3922
Joseph J. Wolk
Phone: +1 732-524-1142
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
DEWA Organises 20th WETEX & 3rd Dubai Solar Show from 23-25 October 201815.10.2018 10:58 | Pressemelding
In a press conference held in Dubai, HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA), announced details of the 20th Water, Energy, Technology, and Environment Exhibition (WETEX 2018) and the 3rd Dubai Solar Show. DEWA organises the two exhibitions at the Dubai International Convention and Exhibition Centre from 23 to 25 October 2018. WETEX 2018, under the theme ‘At the forefront of sustainability,’ will be the biggest in the exhibition’s history, covering 78,413 square metres. It will host 2,100 exhibitors from 53 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005457/en/ DEWA organises 20th WETEX & 3rd Dubai Solar Show from 23-25 October 2018 (Photo: AETOSWire) WETEX is the largest of its kind in the region and one of the biggest specialised exhibitions in the world. It has become an annual event for regional and international companies in the energy, water, clean energy,
Bank of America Reports Third-Quarter 2018 Financial Results15.10.2018 10:54 | Pressemelding
Bank of America reported its third-quarter 2018 financial results today. The news release, supplemental filing and investor presentation can be accessed in the following ways: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005455/en/ Bank of America newsroom at https://newsroom.bankofamerica.com Bank of America Investor Relations website at http://investor.bankofamerica.com Business Wire’s news webpage at http://www.businesswire.com/portal/site/home/news Investor Conference Call information Chief Executive Officer Brian Moynihan and Chief Financial Officer Paul Donofrio will discuss the financial results in a conference call at 8:30 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international), and the conference ID is 79795. Please dial in 10 minutes prior to the start of the call. Investors can also listen to a live audio webcast of the conference cal
Moody’s and Reis Announce Successful Completion of Cash Tender Offer for Shares of Reis15.10.2018 10:00 | Pressemelding
Moody’s Corporation (NYSE:MCO) and Reis, Inc. (NASDAQ:REIS) announce today that Moody’s wholly-owned subsidiary, Moody’s Analytics Maryland Corp., successfully completed the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of Reis at a purchase price of $23.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005308/en/ The tender offer expired at 11:59 p.m., New York City time, on October 12, 2018. The depositary for the tender offer has advised that as of the expiration of the tender offer, a total of 9,800,276 shares of common stock of Reis were validly tendered and not validly withdrawn in the tender offer (excluding shares with respect to which notices of guaranteed delivery were delivered) representing approximately 84.7% of Reis’s outstanding shares of common stock.
Bentley Advances Industrialization of Infrastructure Project Delivery Through ProjectWise Integration with Microsoft 36515.10.2018 09:16 | Pressemelding
The Year in Infrastructure 2018 Conference - Bentley Systems, Incorporated announced the general availability of integration between ProjectWise 365 Services and Microsoft 365. The collaboration capabilities of Microsoft Teams and Microsoft Flow, alongside analytics from Microsoft SharePoint and Microsoft Power BI, can now be applied to mainstream automated digital workflows within ProjectWise. The integration will enable collaborative digital workflows that transcend system boundaries throughout infrastructure capital project delivery, ensuring standards and best practices are propagated across projects, and increasing repeatability, scalability, quality, and predictability—in effect, industrializing project delivery, so that project teams can widely replicate their best projects’ successes. Neil Lee, IT Director - Applications, Mott MacDonald, said, “The integration of ProjectWise and Microsoft Office 365 will be a significant enabler for our ongoing digital strategy for project deli
Siemens and Bentley Systems Announce Integrated Asset Performance Management (APM) Solution for Power Plants15.10.2018 09:12 | Pressemelding
The Year in Infrastructure 2018 Conference – Siemens and Bentley Systems have announced a joint technology and service solution, consisting of their complementary offerings, to speed up the digitalization of power plants and provide intelligent analytics with a range of innovative offerings and managed services solutions. The new service, to be hosted on Siemens’ cloud-based open IoT operating system, MindSphere, will combine Bentley’s advanced asset performance software capabilities with Siemens’ complementary technology and service expertise to empower power plant owners to take full advantage of digitalization, which helps improve maintenance operations and planning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005249/en/ APM for Power Plants combines Bentley's advanced asset performance software capabilities with Siemens' industry and domain expertise. (Photo: Business Wire) Siemens’ asset performance management
Bentley Systems Acquires LEGION, Leading Pedestrian Simulation Software15.10.2018 09:09 | Pressemelding
The Year in Infrastructure 2018 Conference–– Bentley Systems, Incorporated, the leading global provider of comprehensive software solutions for advancing the design, construction, and operations of infrastructure, today announced the acquisition of leading pedestrian simulation software provider LEGION, based in London and supporting more than half of the world’s 40 largest transit agencies. The acquisition augments Bentley’s comprehensive modeling environment with collaborative digital workflows to explore and validate comparative simulations of pedestrian traffic scenarios. LEGION’s pedestrian simulation application offers modeling capabilities of people’s interactions with each other and physical obstacles, and activities, including circulation and evacuations, within public spaces like railway stations, airports, sports arenas, tall buildings, and street level with vehicle interactions. Using LEGION simulation tools in collaborative digital workflows with Bentley’s OpenBuildings De